TECTARIA BIO LLC

Biotech · Private

Cell engineering technology that enhances proteasome function to increase protein production in biomanufacturing cell lines

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Engineered Cell Lines with Activated Proteasomes for Increased Biomanufacturing Efficiency$275,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2208TRAVERSE BIOSCIENCES, INC.——
2209ARIETIS CORPORATION——
2210MBX Biosciences—$95M
2211TECTARIA BIO LLC——
2212PARATEK PHARMACEUTICALS INC—$93M
2213Milestone Pharmaceuticals Inc.—$91M
2214BE COOL PHARMACEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Compositions And Methods For Increased Protein Productionapplication
  • Compositions And Methods For Increased Protein Productionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.